211 related articles for article (PubMed ID: 36413364)
21. Health Care Utilization and Spending in Medicare Advantage vs Traditional Medicare: A Difference-in-Differences Analysis.
Schwartz AL; Zlaoui K; Foreman RP; Brennan TA; Newhouse JP
JAMA Health Forum; 2021 Dec; 2(12):e214001. PubMed ID: 35977297
[TBL] [Abstract][Full Text] [Related]
22. Prostate Cancer Screening Uptake in Transgender Women.
Kalavacherla S; Riviere P; Kalavacherla S; Anger JT; Murphy JD; Rose BS
JAMA Netw Open; 2024 Feb; 7(2):e2356088. PubMed ID: 38353948
[TBL] [Abstract][Full Text] [Related]
23. Association Between Guideline-Discordant Prostate Cancer Imaging Rates and Health Care Service Among Veterans and Medicare Recipients.
Makarov DV; Ciprut S; Walter D; Kelly M; Gold HT; Zhou XH; Sherman SE; Braithwaite RS; Gross C; Zeliadt S
JAMA Netw Open; 2018 Aug; 1(4):e181172. PubMed ID: 30646111
[TBL] [Abstract][Full Text] [Related]
24. Continuity of Care and Health Care Utilization in Older Adults With Dementia in Fee-for-Service Medicare.
Amjad H; Carmichael D; Austin AM; Chang CH; Bynum JP
JAMA Intern Med; 2016 Sep; 176(9):1371-8. PubMed ID: 27454945
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.
Etzioni R; Berry KM; Legler JM; Shaw P
Urology; 2002 Feb; 59(2):251-5. PubMed ID: 11834397
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins.
Vettenranta A; Murtola TJ; Raitanen J; Raittinen P; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
JAMA Oncol; 2022 Jan; 8(1):61-68. PubMed ID: 34817559
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation.
Howard DH; Tangka FK; Guy GP; Ekwueme DU; Lipscomb J
Health Aff (Millwood); 2013 Mar; 32(3):596-602. PubMed ID: 23459740
[TBL] [Abstract][Full Text] [Related]
28. Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.
Macleod LC; Yabes JG; Fam MM; Bandari J; Yu M; Maganty A; Furlan A; Filson CP; Davies BJ; Jacobs BL
Eur Urol Focus; 2020 Mar; 6(2):242-248. PubMed ID: 31031042
[TBL] [Abstract][Full Text] [Related]
29. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
30. [Prostate cancer screening with Prostate-Specific Antigen (PSA) to men over 70 years old in an urban health zone, 2018-2020: A cross-sectional study].
Urquijo-Moraza A; Guinea-Castañares J; Iturralde-Iriso JM
Semergen; 2023; 49(1):101876. PubMed ID: 36462252
[TBL] [Abstract][Full Text] [Related]
31. Low-Value Care at the Actionable Level of Individual Health Systems.
Ganguli I; Morden NE; Yang CW; Crawford M; Colla CH
JAMA Intern Med; 2021 Nov; 181(11):1490-1500. PubMed ID: 34570170
[TBL] [Abstract][Full Text] [Related]
32. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
[TBL] [Abstract][Full Text] [Related]
33. Trends in Use of Low-Value Care in Traditional Fee-for-Service Medicare and Medicare Advantage.
Park S; Jung J; Burke RE; Larson EB
JAMA Netw Open; 2021 Mar; 4(3):e211762. PubMed ID: 33729504
[TBL] [Abstract][Full Text] [Related]
34. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
35. State-Level Variation In Low-Value Care For Commercially Insured And Medicare Advantage Populations.
Do LA; Koethe BC; Daly AT; Chambers JD; Ollendorf DA; Wong JB; Fendrick AM; Neumann PJ; Kim DD
Health Aff (Millwood); 2022 Sep; 41(9):1281-1290. PubMed ID: 36067429
[TBL] [Abstract][Full Text] [Related]
36. Association Between Community-Level Social Risk and Spending Among Medicare Beneficiaries: Implications for Social Risk Adjustment and Health Equity.
Powers BW; Figueroa JF; Canterberry M; Gondi S; Franklin SM; Shrank WH; Joynt Maddox KE
JAMA Health Forum; 2023 Mar; 4(3):e230266. PubMed ID: 37000433
[TBL] [Abstract][Full Text] [Related]
37. Expected population impacts of discontinued prostate-specific antigen screening.
Gulati R; Tsodikov A; Etzioni R; Hunter-Merrill RA; Gore JL; Mariotto AB; Cooperberg MR
Cancer; 2014 Nov; 120(22):3519-26. PubMed ID: 25065910
[TBL] [Abstract][Full Text] [Related]
38. The Utilization and Costs of Grade D USPSTF Services in Medicare, 2007-2016.
Oronce CIA; Fendrick AM; Ladapo JA; Sarkisian C; Mafi JN
J Gen Intern Med; 2021 Dec; 36(12):3711-3718. PubMed ID: 33852141
[TBL] [Abstract][Full Text] [Related]
39. The cost implications of prostate cancer screening in the Medicare population.
Ma X; Wang R; Long JB; Ross JS; Soulos PR; Yu JB; Makarov DV; Gold HT; Gross CP
Cancer; 2014 Jan; 120(1):96-102. PubMed ID: 24122801
[TBL] [Abstract][Full Text] [Related]
40. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
